Ocular Therapeutix annual operating margin
2012
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ocular Therapeutix's operating margin was −519.75% for fiscal 2025.
View full Ocular Therapeutix company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −519.75% | −250.18 pp |
| 2024 | 2024-12-31 | −269.57% | −128.61 pp |
| 2023 | 2023-12-31 | −140.96% | +11.78 pp |
| 2022 | 2022-12-31 | −152.74% | +26.56 pp |
| 2021 | 2021-12-31 | −179.30% | +181.82 pp |
| 2020 | 2020-12-31 | −361.13% | +1668.73 pp |
| 2019 | 2019-12-31 | −2,029.86% | +940.90 pp |
| 2018 | 2018-12-31 | −2,970.75% | +249.37 pp |
| 2017 | 2017-12-31 | −3,220.12% | −924.10 pp |
| 2016 | 2016-12-31 | −2,296.03% | −113.34 pp |
| 2015 | 2015-12-31 | −2,182.69% | +1326.90 pp |
| 2014 | 2014-12-31 | −3,509.59% | +133200.41 pp |
| 2012 | 2012-12-31 | −136,710.00% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −609.34% | −106.77 pp |
| Q1 2026 | 2026-03-31 | −865.46% | −267.99 pp |
| Q4 2025 | 2025-12-31 | −526.50% | −230.44 pp |
| Q3 2025 | 2025-09-30 | −472.35% | −174.14 pp |
| Q2 2025 | 2025-06-30 | −502.57% | −237.44 pp |
| Q1 2025 | 2025-03-31 | −597.47% | −383.46 pp |
| Q4 2024 | 2024-12-31 | −296.06% | −160.61 pp |
| Q3 2024 | 2024-09-30 | −298.20% | −170.80 pp |
| Q2 2024 | 2024-06-30 | −265.13% | −129.68 pp |
| Q1 2024 | 2024-03-31 | −214.00% | −45.40 pp |
| Q4 2023 | 2023-12-31 | −135.45% | +2.10 pp |
| Q3 2023 | 2023-09-30 | −127.41% | +52.65 pp |
| Q2 2023 | 2023-06-30 | −135.45% | +26.91 pp |
| Q1 2023 | 2023-03-31 | −168.60% | −33.37 pp |
| Q4 2022 | 2022-12-31 | −137.55% | +9.09 pp |
| Q3 2022 | 2022-09-30 | −180.06% | −19.37 pp |
| Q2 2022 | 2022-06-30 | −162.37% | +10.28 pp |
| Q1 2022 | 2022-03-31 | −135.23% | +140.28 pp |
| Q4 2021 | 2021-12-31 | −146.63% | +48.54 pp |
| Q3 2021 | 2021-09-30 | −160.69% | +77.67 pp |
| Q2 2021 | 2021-06-30 | −172.65% | +967.19 pp |
| Q1 2021 | 2021-03-31 | −275.51% | +361.28 pp |
| Q4 2020 | 2020-12-31 | −195.17% | +753.46 pp |
| Q3 2020 | 2020-09-30 | −238.36% | +2553.44 pp |
| Q2 2020 | 2020-06-30 | −1,139.83% | +2183.09 pp |
| Q1 2020 | 2020-03-31 | −636.80% | +3358.73 pp |
| Q4 2019 | 2019-12-31 | −948.63% | +2480.54 pp |
| Q3 2019 | 2019-09-30 | −2,791.80% | +183.30 pp |
| Q2 2019 | 2019-06-30 | −3,322.92% | −1229.71 pp |
| Q1 2019 | 2019-03-31 | −3,995.53% | −38.18 pp |
| Q4 2018 | 2018-12-31 | −3,429.17% | −818.08 pp |
| Q3 2018 | 2018-09-30 | −2,975.10% | −69.56 pp |
| Q2 2018 | 2018-06-30 | −2,093.21% | +2093.78 pp |
| Q1 2018 | 2018-03-31 | −3,957.35% | −657.98 pp |
| Q4 2017 | 2017-12-31 | −2,611.09% | −170.38 pp |
| Q3 2017 | 2017-09-30 | −2,905.54% | −968.86 pp |
| Q2 2017 | 2017-06-30 | −4,186.99% | −1668.39 pp |
| Q1 2017 | 2017-03-31 | −3,299.37% | −1004.83 pp |
| Q4 2016 | 2016-12-31 | −2,440.70% | −84.05 pp |
| Q3 2016 | 2016-09-30 | −1,936.69% | +667.97 pp |
| Q2 2016 | 2016-06-30 | −2,518.59% | −419.47 pp |
| Q1 2016 | 2016-03-31 | −2,294.54% | −624.82 pp |
| Q4 2015 | 2015-12-31 | −2,356.65% | −862.20 pp |
| Q3 2015 | 2015-09-30 | −2,604.66% | +2133.80 pp |
| Q2 2015 | 2015-06-30 | −2,099.13% | +4030.77 pp |
| Q1 2015 | 2015-03-31 | −1,669.72% | +23608.06 pp |
| Q4 2014 | 2014-12-31 | −1,494.46% | — |
| Q3 2014 | 2014-09-30 | −4,738.46% | — |
| Q2 2014 | 2014-06-30 | −6,129.90% | — |
| Q1 2014 | 2014-03-31 | −25,277.78% | — |
Over the last five reported fiscal years, Ocular Therapeutix's operating margin decreased from −361.13% to −519.75%, a change of −158.63 percentage points. The latest reported quarter, Q2 2026, shows −609.34%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ocular Therapeutix filings at SEC.gov ↗